Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents.
Indian J Cancer
; 2010 Jul-Sept; 47(3): 248-259
Article
em En
| IMSEAR
| ID: sea-144347
ABSTRACT
Despite significant improvements in the treatment and outcomes of patients with squamous cell carcinoma of the head and neck (SCCHN) that have resulted from technological advances in radiation delivery and the use of cytotoxic chemotherapy, there is still a pressing need for novel therapies. In the last two decades, our understanding of the molecular biological basis of cancer has provided us with a new framework for developing specific targeted therapies. It is likely that the next wave of developments will include active small molecule inhibitors of epidermal growth factor receptor (EGFR) (and other members of the c-erbB family of receptors), antiangiogenic agents, and drugs that can increase proapoptotic signaling in cancer cells. As with cetuximab, it is most likely that these new agents will first find a niche in the context of combination regimens with standard anticancer therapeutics.
Palavras-chave
Texto completo:
1
Índice:
IMSEAR
Assunto principal:
Terapia Biológica
/
Humanos
/
Carcinoma de Células Escamosas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Quimioterapia Adjuvante
/
Apoptose
/
Inibidores da Angiogênese
/
Peptídeos e Proteínas de Sinalização Intracelular
/
Descoberta de Drogas
/
Receptores ErbB
Idioma:
En
Revista:
Indian J Cancer
Ano de publicação:
2010
Tipo de documento:
Article